CD4 and neoplasm: Thus, to address the potential of necroptotic EVs to deliver tumor neoantigens, we compared all the proteins identified in the necroptotic EVs with neoantigens in a dataset derived from B16F10, CT26, 4T1, or CT26 cell lines or in an in silico prediction model, which contains immunogenic antigens recognized by CD4+ T cells that elicit an anti-tumor response.